Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib in the treatment of thyroid cancer.
Ferrari SM, Politti U, Spisni R, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A, Fallahi P. Ferrari SM, et al. Among authors: miccoli p. Expert Rev Anticancer Ther. 2015;15(8):863-74. doi: 10.1586/14737140.2015.1064770. Epub 2015 Jul 7. Expert Rev Anticancer Ther. 2015. PMID: 26152651
Sorafenib and thyroid cancer.
Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ulisse S, Miccoli P, Antonelli A. Fallahi P, et al. Among authors: miccoli p. BioDrugs. 2013 Dec;27(6):615-28. doi: 10.1007/s40259-013-0049-y. BioDrugs. 2013. PMID: 23818056 Review.
New therapies for dedifferentiated papillary thyroid cancer.
Fallahi P, Mazzi V, Vita R, Ferrari SM, Materazzi G, Galleri D, Benvenga S, Miccoli P, Antonelli A. Fallahi P, et al. Among authors: miccoli p. Int J Mol Sci. 2015 Mar 17;16(3):6153-82. doi: 10.3390/ijms16036153. Int J Mol Sci. 2015. PMID: 25789503 Free PMC article. Review.
Aggressive thyroid cancer: targeted therapy with sorafenib.
Corrado A, Ferrari SM, Politti U, Mazzi V, Miccoli M, Materazzi G, Antonelli A, Ulisse S, Fallahi P, Miccoli P. Corrado A, et al. Among authors: miccoli p, miccoli m. Minerva Endocrinol. 2017 Mar;42(1):64-76. doi: 10.23736/S0391-1977.16.02229-X. Epub 2015 Jun 26. Minerva Endocrinol. 2017. PMID: 26112458 Review.
Cabozantinib in Thyroid Cancer.
Fallahi P, Ferrari SM, Di Bari F, Materazzi G, Benvenga S, Miccoli P, Antonelli A. Fallahi P, et al. Among authors: miccoli p. Recent Pat Anticancer Drug Discov. 2015;10(3):259-69. doi: 10.2174/1574892810666150708110816. Recent Pat Anticancer Drug Discov. 2015. PMID: 26152149 Review.
Selective use of vandetanib in the treatment of thyroid cancer.
Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A. Fallahi P, et al. Among authors: miccoli p. Drug Des Devel Ther. 2015 Jul 3;9:3459-70. doi: 10.2147/DDDT.S72495. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26170630 Free PMC article. Review.
Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Ferrari SM, Fallahi P, Politti U, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A. Ferrari SM, et al. Among authors: miccoli p. Front Endocrinol (Lausanne). 2015 Nov 20;6:176. doi: 10.3389/fendo.2015.00176. eCollection 2015. Front Endocrinol (Lausanne). 2015. PMID: 26635725 Free PMC article. Review.
444 results